JWALA PRIYADARSINI Sivaccumar

Dr. JWALA PRIYADARSINI Sivaccumar

Institute of Biostructures and Bioimaging, CNR, Naples, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Annamaria SandomenicoAnnamaria Sandomenico
Annamaria Sandomenico
JSJWALA PRIYADARSINI Sivaccumar
JWALA PRIYADARSINI Sivaccumar
Menotti RuvoMenotti Ruvo
Menotti Ruvo
Antibodies and antibody-derived molecules are continuously developed as both therapeutic agents and key reagents for advanced diagnostic investigations. Their application in these fields has indeed greatly expanded the demand of these molecules and the need for their production in high yield and purity. While full-length antibodies require mammalian expression systems due to the occurrence of functionally and structurally important glycosylations, most antibody fragments and antibody-like molecules are non-glycosylated and can be more conveniently prepared in E. coli-based expression platforms. We propose here an updated survey of the most effective and appropriate methods of preparation of antibody fragments that exploit E. coli as an expression background and review the pros and cons of the different platforms available today. Around 250 references accompany and complete the review together with some lists of the most important new antibody-like molecules that are on the market or are being developed as new biotherapeutics or diagnostic agents.

Verified
Journal Article
Open access
PDF file
JSJWALA PRIYADARSINI Sivaccumar
JWALA PRIYADARSINI Sivaccumar
ALAntonio Leonardi
Antonio Leonardi
EIEmanuela Iaccarino
Emanuela Iaccarino
GCGiusy Corvino
Giusy Corvino
LSluca sanguigno
luca sanguigno
Annamaria SandomenicoAnnamaria Sandomenico
Annamaria Sandomenico
Background: Monoclonal antibodies (mAbs) against cancer biomarkers are key reagents in diagnosis and therapy. One such relevant biomarker is a preferentially expressed antigen in melanoma (PRAME) that is selectively expressed in many tumors. Knowing mAb’s epitope is of utmost importance for understanding the potential activity and therapeutic prospective of the reagents. Methods: We generated a mAb against PRAME immunizing mice with PRAME fragment 161–415; the affinity of the antibody for the protein was evaluated by ELISA and SPR, and its ability to detect the protein in cells was probed by cytofluorimetry and Western blotting experiments. The antibody epitope was identified immobilizing the mAb on bio-layer interferometry (BLI) sensor chip, capturing protein fragments obtained following trypsin digestion and performing mass spectrometry analyses. Results: A mAb against PRAME with an affinity of 35 pM was obtained and characterized. Its epitope on PRAME was localized on residues 202–212, taking advantage of the low volumes and lack of fluidics underlying the BLI settings. Conclusions: The new anti-PRAME mAb recognizes the folded protein on the surface of cell membranes suggesting that the antibody’s epitope is well exposed. BLI sensor chips can be used to identify antibody epitopes.

10 August 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JSJWALA PRIYADARSINI Sivaccumar
JWALA PRIYADARSINI Sivaccumar
EIEmanuela Iaccarino
Emanuela Iaccarino
AOAngela Oliver
Angela Oliver
MCMaria Cantile
Maria Cantile
POPierpaolo Olimpieri
Pierpaolo Olimpieri
Annamaria SandomenicoAnnamaria Sandomenico
Annamaria Sandomenico
Drug development in recent years is increasingly focused on developing personalized treatments based on blocking molecules selective for therapeutic targets specifically present in individual patients. In this perspective, the specificity of therapeutic targets and blocking agents plays a crucial role. Monoclonal antibodies (mAbs) and their surrogates are increasingly used in this context thanks to their ability to bind therapeutic targets and to inhibit their activity or to transport bioactive molecules into the compartments in which the targets are expressed. Small antibody-like molecules, such as Fabs, are often used in certain clinical settings where small size and better tissue penetration are required. In the wake of this research trend, we developed a murine mAb (3D1) neutralizing the activity of Nodal, an oncofetal protein that is attracting an ever-increasing interest as a selective therapeutic target for several cancer types. Here, we report the preparation of a recombinant Fab of 3D1 that has been humanized through a computational approach starting from the sequence of the murine antibody. The Fab has been expressed in bacterial cells (1 mg/L bacterial culture), biochemically characterized in terms of stability and binding properties by circular dichroism and bio-layer interferometry techniques and tested in vitro on Nodal-positive cancer cells.